The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 08, 2025
Filed:
Aug. 12, 2022
Inovio Pharmaceuticals, Inc., Plymouth Meeting, PA (US);
Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);
Amy-Lee Bredlau, Mahopac, NY (US);
Israel Lowy, Dobbs Ferry, NY (US);
Jeffrey Skolnik, Cherry Hill, NJ (US);
Jian Yan, Wallingford, PA (US);
Bernadette Ferraro, San Diego, CA (US);
Jewell Walters, Poway, CA (US);
Albert J. Sylvester, Iii, Croydon, PA (US);
Kimberly A. Kraynyak, Norristown, PA (US);
Matthew P. Morrow, Malvern, PA (US);
Elisabeth Gillespie, Horsham, PA (US);
Inovio Pharmaceuticals, Inc., Plymouth Meeting, PA (US);
Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);
Abstract
Provided herein are methods of treating brain cancer in a subject, comprising evaluating one or more biological samples from a subject who has brain cancer for the presence of a miRNAs and administering interleukin-12 (IL-12); an immunogenic composition of human telomerase reverse transcriptase (hTERT), Wilms Tumor-1 (WT-1), and prostate specific membrane antigen (PSMA); and an anti-programmed cell death receptor 1 (PD-1) antibody to said subject if the subject has an increased expression level of the mIR-331-3p miRNA or isomiRs thereof and the miR-1537-3p miRNA or isomiRs thereof relative to a control population of subjects. Also provided herein are methods of treating brain cancer in a subject, comprising measuring an expression level of at least one mRNA biomarker selected from SYNGR3, OTX1, GABBR2, LHX1, CADM3, MLLT11, MNX1, GRB14, SLC34A2, PHYHIP, WNT10B, SLC17A6, CRLF1, HOXD13, TGFβR3, UBA7, SFRP4, or any combination thereof, in a tumor sample from a subject and administering IL-12; an immunogenic composition hTERT, WT-1, and PSMA; and an anti-PD-1 antibody to said subject if the expression level of SYNGR3, OTX1, GABBR2, LHX1, CADM3, MLLT11, MNX1, GRB14, SLC34A2, PHYHIP, WNT10B, SLC17A6, CRLF1 and HOXD13 is decreased or if the expression level of TGFβR3, UBA7, SFRP4 is increased.